Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

506.08 +3.16 (+0.63%)
Streaming Delayed Price Updated: 12:18 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Via The Motley Fool
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market. 
Via MarketBeat
Topics Economy Supply Chain
Exposures Economy Supply Chain
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) is showing promising signs of setting up for a breakout.
Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout. 
Via Chartmill
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
Via Benzinga
If I Could Buy Only 1 Growth Stock, This Would Be It
Via The Motley Fool
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Via Benzinga
Analyst Expectations For Vertex Pharmaceuticals's Future
Via Benzinga
Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever
Via The Motley Fool
3 Reasons to Avoid VRTX and 1 Stock to Buy Instead
Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%. 
Via StockStory
Topics Stocks
Exposures US Equities
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
Which S&P500 stocks are moving on Monday?
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
3 Magnificent Growth Stocks to Buy in March
Via The Motley Fool
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
Via Benzinga
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales. 
Via Benzinga
Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids?
New compound mimics natural molecule in cannabis plant, providing pain relief without addictive side effects. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Good technical signals and a possible breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) has a strong technical rating of 9 out of 10, indicating a potential breakout. 
Via Chartmill
5 Top Stocks to Buy in March
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
3 Magnificent Growth Stocks to Buy Right Now
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Via The Motley Fool
3 Stocks That Could Trounce the Market in 2025
Via The Motley Fool
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
Via The Motley Fool
The Ultimate Healthcare Stock to Buy With $500 Right Now
Via The Motley Fool
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Via The Motley Fool
Exposures Product Safety
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect. 
Via StockStory
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
Via The Motley Fool
This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.